ReviewDiabetologia2017
Lifestyle and precision diabetes medicine: will genomics help optimise the prediction, prevention and treatment of type 2 diabetes through lifestyle therapy?
Review in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 32 citations in OpenAlex.
- Joint association of physical activity and sedentary time with all-cause and cardiovascular mortality among advanced CKM syndrome participants, insights from NHANES 2007-2018.Clinical and experimental medicine · 2026Article
- Nonlinear association of physical activity with early cardiovascular-kidney-metabolic syndrome risk: a comprehensive analysis of NHANES data from 2007 to 2018.BMC public health · 2025Article
- Diabetes and its Silent Partner: A Critical Review of Hyperinsulinemia and its Complications.Current diabetes reviews · 2025Review
- Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice.Nature reviews. Endocrinology · 2023Review
- Do gene-environment interactions have implications for the precision prevention of type 2 diabetes?Diabetologia · 2022Review
- Predicting Sensitivity to Adverse Lifestyle Risk Factors for Cardiometabolic Morbidity and Mortality.Nutrients · 2022Article
- Multi-target regulation of intestinal microbiota by berberine to improve type 2 diabetes mellitus.Frontiers in endocrinology · 2022Review
- Interaction between dietary branched-chain amino acids and genetic risk score on the risk of type 2 diabetes in Chinese.Genes & nutrition · 2021Article
- Precision Medicine in Non-Communicable Diseases.High-throughput · 2020Article
- Inflammatory cytokines in type 2 diabetes mellitus as facilitators of hypercoagulation and abnormal clot formation.Cardiovascular diabetology · 2019Article
- Precision Medicine and Exercise Therapy in Duchenne Muscular Dystrophy.Sports (Basel, Switzerland) · 2019Article
- A Global Overview of Precision Medicine in Type 2 Diabetes.Diabetes · 2018Article
- Genotype-Based Recall Studies in Complex Cardiometabolic Traits.Circulation. Genomic and precision medicine · 2018Review
- Gene-lifestyle interplay in type 2 diabetes.Current opinion in genetics & development · 2018Review
- Pathophysiology of Type 2 Diabetes in Koreans.Endocrinology and metabolism (Seoul, Korea) · 2018Review
- Use of Metabolomics in Improving Assessment of Dietary Intake.Clinical chemistry · 2018Review
- Review
- Precision diabetes: a realistic outlook on a promising approach.Diabetologia · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Precision diabetes medicine, the optimisation of therapy using patient-level biomarker data, has stimulated enormous interest throughout society as it provides hope of more effective, less costly and safer ways of preventing, treating, and perhaps even curing the disease. While precision diabetes medicine is often framed in the context of pharmacotherapy, using biomarkers to personalise lifestyle recommendations, intended to lower type 2 diabetes risk or to slow progression, is also conceivable. There are at least four ways in which this might work: (1) by helping to predict a person's susceptibility to adverse lifestyle exposures; (2) by facilitating the stratification of type 2 diabetes into subclasses, some of which may be prevented or treated optimally with specific lifestyle interventions; (3) by aiding the discovery of prognostic biomarkers that help guide timing and intensity of lifestyle interventions; (4) by predicting treatment response. In this review we overview the rationale for precision diabetes medicine, specifically as it relates to lifestyle; we also scrutinise existing evidence, discuss the barriers germane to research in this field and consider how this work is likely to proceed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.